Potoos Research Services MarketMind courseBack to home
RESULTS / Q2 FY27

Jubilant Pharmova Q2 results 2026: profit down 74%

Jubilant Pharmova, the pharmaceutical and radiopharmaceutical company, reported consolidated revenue from operations of Rs 23,700 million (Rs 2,370 crore) and profit after tax of Rs 310 million (Rs 31 crore) for July to September 2026.

Published 18 November 2026 · Potoos Research Services

The short answer. Revenue rose 20.52% from a year earlier but profit after tax fell 74.15%. The company says margins fell because some high-margin radiopharmaceutical products were not available and because of extra repair costs at its Montreal plant. Its sterile injectables contract business went from a segment profit to a small segment loss. No dividend was declared and the auditor raised no issue.

Quarter at a glance

Consolidated figures (the company plus its subsidiaries) in Rs million, as reported. Rs 10 million is Rs 1 crore. Change compares the same quarter a year earlier.

MeasureJul-Sep 2026Jul-Sep 2025Change
Revenue from operations23,70019,664+20.52%
Other income14498+46.94%
Total expenses23,22717,800+30.49%
of which employee benefits8,2986,362+30.43%
of which other expenses5,3963,923+37.55%
of which depreciation, amortisation and impairment1,3481,048+28.63%
of which finance costs584502+16.33%
Exceptional itemsnil(58)n.a.
Profit before tax6171,903-67.58%
Tax307704-56.39%
Profit after tax3101,199-74.15%
Profit belonging to owners3121,203-74.06%
Earnings per share, basic (Rs)1.977.59-74.04%

Source: Jubilant Pharmova unaudited consolidated financial results, PDF page 11. Brackets mean a cost. Percentages are recomputed from the filing figures. The filing's notes this quarter do not describe the year-ago exceptional item.

Why did profit fall when revenue rose 21%?

Costs rose faster than revenue. Employee costs rose 30.43% and other expenses 37.55%, against revenue growth of 20.52%. Depreciation rose 28.63%.

The company's press release gives the reasons in the chairmen's comment: "EBITDA margins declined year-on-year, primarily due to the unavailability of high-margin SPECT radiopharmaceutical products in the Radiopharmaceuticals business. Additionally, margins were impacted by higher operating expenses, including incremental remediation costs at the CMO Montreal facility." It adds that profit margins fell "due to lower operating profitability and increase in depreciation." Source: press release, PDF page 2.

Some terms: EBITDA is profit before interest, tax, depreciation and amortisation. The release puts it at Rs 255 crore, a margin of 10.7% of revenue, against Rs 351 crore and 17.8% a year earlier. Radiopharmaceuticals are medicines with a small amount of radioactive material, used mainly in medical scans. SPECT is one type of such scan. Remediation means fixing problems at a plant, usually after a regulator's inspection. CMO Montreal is the company's contract manufacturing plant in Montreal, Canada.

How did each business do?

Segment revenue and segment result (profit before tax, exceptional items and interest) in Rs million, as reported.

BusinessRevenue Jul-Sep 2026Revenue Jul-Sep 2025Result Jul-Sep 2026Result Jul-Sep 2025
Radiopharma10,0938,971698955
Allergy immunotherapy2,2951,940657749
Contract manufacturing, sterile injectables (CDMO)5,5964,115(42)710
Contract research and manufacturing (CRDMO)3,4483,125200290
Generics2,7411,67051(3)
Proprietary novel drugsnilnil(102)(29)

Source: segment note 2, PDF page 14. Segment revenue is before inter-segment sales are removed.

The biggest swing is in sterile injectables contract manufacturing. Its revenue rose 35.99%, but the segment went from a profit of Rs 710 million to a loss of Rs 42 million. The press release says revenue in this business grew "due to incremental revenue from Line 3" (its third production line) and that margins were lower "due to higher operating expenses including incremental remediation cost at Montreal facility." Radiopharma revenue rose 12.51% while its result fell 26.91%.

Two points a reader may notice in the press release. First, the release gives this business's revenue as Rs 522 crore, up 33%, while the filing's segment table gives Rs 5,596 million (Rs 559.6 crore), up 35.99%. The release does not explain the difference, and this page uses the filing's figures. Second, the release reports EBITDA of Rs 37 crore for this business, which is before depreciation and interest, so it does not conflict with the segment loss in the filing, which is after depreciation.

Why was the tax rate so high?

Tax was Rs 307 million on profit before tax of Rs 617 million, or 49.8% (our arithmetic), against 37.0% a year earlier. It was made up of a current tax credit of Rs 52 million and a deferred tax charge of Rs 359 million. The filing does not explain this mix.

Debt raised after the quarter

On 12 October 2026 the board approved raising up to Rs 8,000 million through non-convertible debentures (NCDs, a kind of bond that cannot be turned into shares), in units of Rs 1,00,000 each. On Thursday 5 November 2026 the company allotted unsecured NCDs of Rs 8,000 million. The press release says the money will go towards refinancing debt and capital spending. Consolidated borrowings were Rs 34,332 million (non-current) and Rs 4,590 million (current) at 30 September 2026. Source: note 4, PDF page 15, consolidated assets and liabilities, PDF page 12 and press release, PDF page 2.

Dividend and auditor

The board did not declare a dividend, buyback or bonus with these results. The auditor, Walker Chandiok & Co LLP, gave unmodified conclusions on both the standalone and consolidated results, which means it did not report a problem (PDF pages 2, 3, 8 and 9). On its own (standalone), the parent company made a profit of Rs 76 million from continuing operations. The board met on Friday 13 November 2026, from 17:00 to 18:30 IST (outcome letter, PDF page 1).

Sources

Data source: the data on this page is referenced from BSE, bseindia.com. The documents are linked in the Sources list above. BSE has not reviewed or approved this page.

Sources checked on 17 November 2026. Information cutoff: 17 November 2026, 13:00 IST

Common questions

How much did Jubilant Pharmova earn in Q2 FY27?

Consolidated profit after tax was Rs 310 million (Rs 31 crore), down 74.15% from Rs 1,199 million a year earlier. Revenue from operations rose 20.52% to Rs 23,700 million.

Why did Jubilant Pharmova's profit fall?

The company says margins fell mainly because high-margin SPECT radiopharmaceutical products were not available, and because of higher operating costs including remediation at its Montreal plant. Depreciation also rose.

Did Jubilant Pharmova declare a dividend?

No. The board approved the quarterly results only. No dividend, buyback or bonus was announced.

How much did Jubilant Pharmova raise through NCDs?

It allotted unsecured non-convertible debentures of Rs 8,000 million on 5 November 2026. The press release says the money is for refinancing debt and capital spending.

Who writes this

Potoos Research, SEBI-registered Research Analyst. Registration number INH000027380. SEBI is the Securities and Exchange Board of India.

Track record · About Potoos and the analyst.